Yunying Medical
Personalized oncology diagnostics and related reagent development
About Yunying Medical
Yunying Medical, founded in 2015, is a high-tech enterprise established by a group of returning overseas students, advocating for precision medicine in oncology. The company focuses on providing personalized molecular diagnosis services and developing related reagents for cancer treatment. It offers a comprehensive precision medicine solution that covers early screening, targeted drug testing, and integrated drug development, utilizing technologies like genetic mutation and methylation detection.
The company was co-founded by CEO Dr. Daoyun Zhang and CTO Dr. Ziying Gong. Dr. Zhang holds a Ph.D. from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and was a postdoctoral fellow at Johns Hopkins University School of Medicine. Dr. Gong, also a Ph.D. from the Shanghai Institutes for Biological Sciences, is a molecular genetics expert who has led the development of the company's core technologies such as DNAplus™, Alldetect™, and AllNGS™. The founding team also includes biologists and bioinformatics experts from institutions like Johns Hopkins University and the National Cancer Institute.
Yunying Medical serves healthcare professionals and has a technical service network covering over 1,000 hospitals across five major regions in China. The company operates NGS sequencing labs, PCR labs, molecular labs, a GMP workshop, and a medical testing laboratory. Its business model involves providing clinical diagnosis for targeted drug use and tumor treatment monitoring, having developed its own capture reagents for second-generation sequencing. The firm has received B-round funding and counts investors like Jintan Capital among its backers.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2026 | — | — | CUFE Rising Capital | ↗ |
| LATE VC✓Equity / VC | Apr 2020 | $14M | $55M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Yunying Medical is 380 monthly website visits, up 8.6% over the last three months. Yunying Medical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yunying Medical in the Huangpu ecosystem
The Yunying Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- CCCUFE Rising Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yunying Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yunying Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









